RIPK2

BOSTON--(BUSINESS WIRE)-- Odyssey Therapeutics, Inc., a biotechnology company pioneering next-generation precision immunomodulators and oncology medicines, will present data highlighting three of its immunology programs at the American College of Rheumatology (ACR) Convergence 2023 meeting in San Diego, California, November 10-15, 2023. Odyssey’s oral and poster presentations will unveil the first public data for three novel therapeutic approaches to treat large populations with underserved inflammatory and autoimmune diseases. The receptor interacting protein kinase 2 (RIPK2) and interleukin-1 receptor-associated kinase 4 (IRAK4) scaffolding inhibitors, as well as tumor necrosis factor receptor-2 (TNFR2) agonist for regulatory T (Treg) cell modulation, represent targets and approaches of high interest in the pharmaceutical industry, given their broad potential to treat inflammatory disease. “Odyssey’s team of expert drug hunters are tirelessly working to pioneer groundbreaking therapeutic strategies for the management of autoimmune disease,” said Gary D. Glick, Ph.D., founder and CEO of Odyssey Therapeutics. “At ACR, we’ll give patients, researchers and investors the first look at our RIPK2 and IRAK4 scaffolding inhibitors, as well as TNFR2 agonist for Treg cell modulation. These therapies can offer transformative benefits for patients, and the findings shared at ACR reflect significant scientific progress and achievement by our team to understand and solve complex biology with small molecule and protein therapeutics.” Oral Presentation Title: Discovery of First-in-Class IRAK4 Scaffolding Inhibitors for the Treatment of Inflammatory Disorders Abstract number: 2505 Session type: Abstract Session Date and time: Tuesday, November 14, from 4-5:30 p.m. PST Poster Presentations Title: Discovery of a RIPK2 Scaffolding Inhibitor for the Treatment of Joint Autoimmune Diseases Abstract number: 0061 Session type: Poster Session A Date and time: Sunday, November 12, from 9-11 a.m. PST Title: Anti-TNFR2 VHH Agonistic Antibodies Promote and Stabilize Treg Immunosuppressive Activity Abstract number: 0068 Session type: Poster Session A Date and time: Sunday, November 12, from 9-11 a.m. PST About Odyssey Therapeutics Odyssey Therapeutics is a biotechnology company focused on discovering, developing and commercializing the next generation of immunomodulators and oncology medicines. Composed of an expert team of drug hunters, scientists and industry leaders in foundational biology, chemistry and data sciences, Odyssey is transforming drug discovery to accelerate and drive the creation and efficient delivery of life-enhancing precision medicines to patients. For more information, please visit odysseytx.com and follow Odyssey Therapeutics on X (formerly Twitter) and LinkedIn.

SUZHOU, China, May 24, 2023 /PRNewswire/ -- Accropeutics Bioscience announced that its oral small molecule TYK2/JAK1 inhibitor AC-201 has been approved by the Australian Human Research Ethics Committee (HREC) to launch a clinical phase I trial in Australia. The trial will be a randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and food effects of AC-201 in healthy adults. AC-201 is a novel small molecule inhibitor of TYK2/JAK1 with high activity, selectivity, and safety window. The preclinical studies have shown that AC-201 effectively binds to the pseudo kinase domain (JH2) of TYK2/JAK1, stabilizing the self-inhibitory conformation of the pseudo kinase domain on the kinase domain, thereby inhibiting the function of TYK2/JAK1 kinase. It demonstrated significant efficacy in multiple animal models of diseases, including psoriasis, and is intended for the treatment of psoriasis and other inflammatory and autoimmune diseases. As an oral drug candidate, AC-201 may provide convenience and efficacy with good safety for psoriasis patients. Dr. Xiaohu Zhang, Co-founder and CEO of Accropeutics Bioscience, said: "AC-201 is the third oral small molecule drug candidate developed by Accropeutics Bioscience to enter the clinical stage. Our company has obtained three clinical approvals this year and five since December 2021. We are committed to advancing these programs and aspire to bring relief to patients globally through these drug candidates ." About Accropeutics Bioscience Accropeutics Bioscience is a clinical-stage biotech company with a core focus on molecular mechanisms of regulated cell death and related pathogenesis in human diseases. The company has developed a robust portfolio of innovative compounds in various stages of development, spanning from lead optimization to clinical trials. RIPK1 inhibitor AC-003 was approved for clinical testing by FDA and NMPA in December 2021 and August 2022, respectively. The phase I trial of AC-003 is wrapping up and a phase Ib-II trial is planned for aGVHD. In the Phase I study, AC-003 was rapidly absorbed in the gastrointestinal tract after oral administration, with a peak time of 1-2 hours. The peak concentration and exposure increased linearly for the 10-480 mg dose groups, and there was no drug accumulation after multiple dose administration. Pharmacokinetic parameters supported a once-daily dosing regimen. AC-003 was well tolerated with only grade 1 adverse events reported in the Chinese (Chinese, ethnic) and US (Caucasian, African-American, Asian) participants. RIPK2 inhibitor AC-101 was approved by HREC in March 2023 and is currently in Phase I in Australia. AC-201, a selective TYK2/JAK1 inhibitor with huge potential for treating inflammatory and autoimmune diseases, was approved by HREC in May 2023 and is scheduled to launch clinical trial in Australia in the near future. The company has multiple compounds in PCC and preclinical stages. Accropeutics Bioscience owns global rights of all its assets with more than 10 patents issued in China, Japan, Korea, US and EU. Media Contact: Jie Xu, [email protected] SOURCE Accro Bioscience (Suzhou) Limited

Michel Stoupak/NurPhoto via Getty Images Atomwise, which focuses on using artificial intelligence (AI) to discover new drugs, inked a strategic research-and-development deal with Sanofi, in which the companies will use the AtomNet platform to identify and research up to five drug targets. Under the terms of the deal, Sanofi will pay Atomwise $20 million upfront to identify, synthesize, and advance lead compounds for up to five targets. A range of research, development and sales milestones could exceed $1 billion. Atomwise is also eligible for tiered royalties of any products from the partnership. AtomNet uses deep learning for structure-based drug design. This leverages Atomwise’s proprietary library of more than three trillion synthesizable compounds. “At Sanofi, we are committed to bringing higher quality medicines to patients faster, empowered by our advanced AI drug discovery engine,” Frank Nestle, Global Head of Research and chief scientific officer at Sanofi, said. “We are excited to partner with Atomwise, given their leadership in the field of virtual screening and AI-based molecular design. Together, we aim at making the drug discovery process more efficient and effective in particular when very limited information is available to support drug design.” Atomwise has a large pipeline of wholly-owned compounds: three in immunology targeting TYK2, RIPK1 and RIPK2 and 33 for undisclosed indications and targets. It also has four co-development partnerships in oncology, hematology and immunology, as well as academic partnerships. Its biopharma partners include Eli Lilly, Bayer, GC Pharma, Hansho Pharma and BridgeBio Therapeutics. Earlier this month, Sanofi entered into a collaboration deal with Innovent Biologics to bring drugs to China for difficult-to-treat cancers. That deal focuses on two of Sanofi’s oncology assets, a Phase III trial of tusamitamab ravtansine, an antibody-drug conjugate against CEACAM5, and a Phase II study of Sanofi’s non-alpha IL-2 (SAR444245) with sintilimab, the leading checkpoint inhibitor in China. Sanofi is eligible for up to €80 million (approximately $81.50 million) in development milestone payments and royalties on the net sales of tusamitinab. Innovent will be eligible to receive up to €60 million (about $61.12 million) in milestone payments on net sales of SAR444245 if it is approved in China. Sanofi also agreed to invest €300 million (approximately $305.61 million) in Innovent shares. In a statement, Michael Yu, Ph.D., founder, chairman and CEO of Innovent, said, “This strategic collaboration with Sanofi, a leading global pharmaceutical company, opens the pathway to great synergy for accelerating the pace of innovation. This pioneering partnership will leverage the synergy between Sanofi and Innovent’s pipeline and R&D resources with the mutual aim to address major unmet medical needs for cancer patients. We hope this agreement will be a great start of the two parties’ long-term partnership, and we look forward to bringing more innovative therapies to patients.” Of the Atomwise deal, Abraham Heifets, co-founder and CEO of Atomwise, said, “At Atomwise, our mission is to use our unique technology to make better medicines, faster, by unlocking targets that have been inaccessible to traditional small molecule discovery approaches. We are pleased to enter into this collaboration with Sanofi, which serves as continued validation of the important role that AI-powered platforms will play in accelerating the discovery of new therapies for diseases and conditions that may have gone untreated due to challenging or uncharacterized drug targets.”